izpis_h1_title_alt

Tumor radiosensitization by gene electrotransfer-mediated double targeting of tumor vasculature
ID Savarin, Monika (Author), ID Žnidar, Katarina (Author), ID Serša, Gregor (Author), ID Komel, Tilen (Author), ID Čemažar, Maja (Author), ID Kamenšek, Urška (Author)

.pdfPDF - Presentation file, Download (6,26 MB)
MD5: BE54801510FDF1DEC54EB400AE854E66
URLURL - Source URL, Visit https://www.mdpi.com/1422-0067/24/3/2755 This link opens in a new window

Abstract
Targeting the tumor vasculature through specific endothelial cell markers involved in different signaling pathways represents a promising tool for tumor radiosensitization. Two prominent targets are endoglin (CD105), a transforming growth factor β co-receptor, and the melanoma cell adhesion molecule (CD1046), present also on many tumors. In our recent in vitro study, we constructed and evaluated a plasmid for simultaneous silencing of these two targets. In the current study, our aim was to explore the therapeutic potential of gene electrotransfer-mediated delivery of this new plasmid in vivo, and to elucidate the effects of combined therapy with tumor irradiation. The antitumor effect was evaluated by determination of tumor growth delay and proportion of tumor free mice in the syngeneic murine mammary adenocarcinoma tumor model TS/A. Histological analysis of tumors (vascularization, proliferation, hypoxia, necrosis, apoptosis and infiltration of immune cells) was performed to evaluate the therapeutic mechanisms. Additionally, potential activation of the immune response was evaluated by determining the induction of DNA sensor STING and selected pro-inflammatory cytokines using qRT-PCR. The results point to a significant radiosensitization and a good therapeutic potential of this gene therapy approach in an otherwise radioresistant and immunologically cold TS/A tumor model, making it a promising novel treatment modality for a wide range of tumors.

Language:English
Keywords:gene electrotransfer, adenocarcinom, radiosensitization, silencing plasmid, antivascular shRNA, CD105, CD1046, DNA sensors, murine mammary adenocarcinoma TS/A
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:ZF - Faculty of Health Sciences
MF - Faculty of Medicine
BF - Biotechnical Faculty
Publication status:Published
Publication version:Version of Record
Year:2023
Number of pages:14 str.
Numbering:Vol. 24, iss. 3, art. 2755
PID:20.500.12556/RUL-155597 This link opens in a new window
UDC:602
ISSN on article:1422-0067
DOI:10.3390/ijms24032755 This link opens in a new window
COBISS.SI-ID:140588547 This link opens in a new window
Publication date in RUL:08.04.2024
Views:419
Downloads:55
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:International journal of molecular sciences
Shortened title:Int. j. mol. sci.
Publisher:MDPI
ISSN:1422-0067
COBISS.SI-ID:2779162 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:genski elektroprenos, adenokarcinom, radiosensitizacija

Projects

Funder:ARRS - Slovenian Research Agency
Project number:Z3-1873
Name:Nov pristop žilno ciljane terapije, kjer z gensko terapijo utišamo dve neodvisni signalni poti, v kombinaciji z radioterapijo

Funder:ARRS - Slovenian Research Agency
Project number:P3-0003
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back